Market Place
Sourcing Support
Virion Completes Enrollment of Phase 1b Chronic Hepatitis B Trial
10 Jan 2025 //
PR NEWSWIRE
Virion Reports Clinical Responses with VRON-0200 at AASLD 2024
19 Nov 2024 //
PR NEWSWIRE
Virion: Positive Phase 1b VRON-0200 Immunogenicity In HBV At EASL
05 Jun 2024 //
PR NEWSWIRE
Ocean Bio: JV Partner Virion`s VRON-0200 Shows Positive HBV Immunogenicity
05 Jun 2024 //
GLOBENEWSWIRE
Ocean Congratulates Virion, on Promising First-Ever Human Ph 1B Safety Data
28 Mar 2024 //
GLOBENEWSWIRE
Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200 at Meeting
27 Mar 2024 //
PR NEWSWIRE
Ocean Announces Joint Venture Partner, Virion to Present Data as Presentation
29 Feb 2024 //
GLOBENEWSWIRE
Ocean Announces First Patients Dosed by Virion in Ph 1b of Novel Immunotherapy
26 Oct 2023 //
GLOBENEWSWIRE
Ocean Biomedical and Virion Therapeutics Form Joint Venture
12 Oct 2023 //
GLOBENEWSWIRE
Virion Presents VRON-0200 Preclinical Data Showing Direct Correlations
21 Jun 2023 //
PR NEWSWIRE
Virion Presents Promising Cancer Data When Using Modifier-Based Immunotherapy
06 Mar 2023 //
PR NEWSWIRE
Center for Breakthrough Medicines and Virion Therapeutics Announce Partnership
22 Feb 2023 //
PR NEWSWIRE
CBM, Virion Partner on CD8+ T cell-based Clinical Development Programs
22 Feb 2023 //
CONTRACT PHARMA
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.